Sam Fazeli
speaker
906 appearances
5 recordings
1 series
first heard Oct 2025
last heard 31 Mar
Sam Fazeli’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 5 in all, peaking in Mar 2026 with 2.
Appearances
Okay so I suspect you're going to tell me that it's my problem to go and figure out how DB11 and DB05 impact DB09 and DB03 use.
It's unfair because I didn't put it on my list of questions when I sent it to you.
Do you have on top of your mind the percentage of patients who present metastatic disease having been through surgery and adjuvant therapy?
Do you have it?
It's probably in the epi data that you've been providing.
So I'll go back.
It's on your website again, right?
Right.
A couple of questions on HR positive.
I mean, you didn't really this wasn't a meeting about the oral certs, but I think this question was posed during the analyst meeting, too.
But but if you wanted to just touch on it here quickly, what does obviously you have some some potential competitors in the space of oral certs, Rosh.
et cetera.
So what does, and Rush did have some data, which was the Avera, or as I call it, EV era, which is I think what it's meant to be, trial.
How does that, what does that mean for the Serena 4 and the adjuvant Cambria studies?
Just to put again into context, companies are trying to develop
oral versions of drugs that impact the estrogen receptor complex versus what had been used before, which was injections and probably not as well tolerated as it should be.
So do you want to just tell us about that a little bit?
Well, you've answered my next question.
So that's brilliant.
So there is an opportunity to reduce at least ESR1 emergence mutation.
Showing 781–800 of 906 · page 40 of 46
← Previous
Next →